Fuan Pharmaceutical (300194.SZ): Cefazolin Sodium Receives Marketing Approval

Zhito Finance APP News: Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Chongqing Bosheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Bosheng Pharmaceutical"), recently received a marketing application approval notice for a chemical active pharmaceutical ingredient (API) issued by the National Medical Products Administration. The API is "Cefazolin Sodium." The marketing approval of the aforementioned API product will allow it to be used in domestically marketed formulations, further enriching the subsidiary's product line.